CN108697727A - 治疗和预防hiv和aids的方法 - Google Patents
治疗和预防hiv和aids的方法 Download PDFInfo
- Publication number
- CN108697727A CN108697727A CN201780010879.XA CN201780010879A CN108697727A CN 108697727 A CN108697727 A CN 108697727A CN 201780010879 A CN201780010879 A CN 201780010879A CN 108697727 A CN108697727 A CN 108697727A
- Authority
- CN
- China
- Prior art keywords
- hiv
- administered
- efda
- once
- dosing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110783129.4A CN113509480A (zh) | 2016-02-12 | 2017-02-10 | 治疗和预防hiv和aids的方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294576P | 2016-02-12 | 2016-02-12 | |
| US62/294576 | 2016-02-12 | ||
| US201662297657P | 2016-02-19 | 2016-02-19 | |
| US62/297657 | 2016-02-19 | ||
| PCT/US2017/017283 WO2017139519A1 (en) | 2016-02-12 | 2017-02-10 | Methods for treatment and prophylaxis of hiv and aids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110783129.4A Division CN113509480A (zh) | 2016-02-12 | 2017-02-10 | 治疗和预防hiv和aids的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108697727A true CN108697727A (zh) | 2018-10-23 |
Family
ID=58057333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110783129.4A Pending CN113509480A (zh) | 2016-02-12 | 2017-02-10 | 治疗和预防hiv和aids的方法 |
| CN201780010879.XA Pending CN108697727A (zh) | 2016-02-12 | 2017-02-10 | 治疗和预防hiv和aids的方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110783129.4A Pending CN113509480A (zh) | 2016-02-12 | 2017-02-10 | 治疗和预防hiv和aids的方法 |
Country Status (37)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113194959A (zh) * | 2018-12-20 | 2021-07-30 | 默沙东公司 | Nrtti化合物的新型结晶形式 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | Combination drug therapy |
| WO2020007070A1 (zh) * | 2018-07-02 | 2020-01-09 | 河南真实生物科技有限公司 | 4'-取代核苷的晶型、制备和应用 |
| US12005072B2 (en) | 2018-07-17 | 2024-06-11 | Merck Sharp & Dohme Llc | HIV drug combination for increasing barrier against resistance |
| AU2020211600A1 (en) | 2019-01-25 | 2021-07-22 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| MA55200A (fr) * | 2019-03-06 | 2022-01-12 | Glaxosmithkline Ip No 2 Ltd | Composés utiles dans la thérapie du vih |
| CN114502175B (zh) | 2019-07-27 | 2025-02-25 | 腾盛博药生物科技有限公司 | 腺苷衍生物和包含其的药物组合物 |
| WO2023196832A2 (en) * | 2022-04-06 | 2023-10-12 | Brii Biosciences, Inc. | Pharmaceutical composition and method for treatment of human immunodeficiency virus infections |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050277616A1 (en) * | 1995-06-07 | 2005-12-15 | Howard Owens | Thymine nucleosides with anti-hepatitis B virus activity |
| US7339053B2 (en) * | 2004-03-24 | 2008-03-04 | Yamasa Corporation | 4′-C-substituted-2-haloadenosine derivative |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514466C (en) | 2003-02-19 | 2015-05-26 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections |
| US8513205B2 (en) * | 2008-04-11 | 2013-08-20 | Yale University | Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase |
| WO2012099630A1 (en) * | 2011-01-20 | 2012-07-26 | University Of Rochester | Compositions and methods for treating or preventing a retrovirus infection |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| WO2017053216A2 (en) | 2015-09-23 | 2017-03-30 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof |
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| EP3454868A4 (en) * | 2016-05-12 | 2019-12-18 | Merck Sharp & Dohme Corp. | ACTIVE SUBSTANCE RELEASE SYSTEM FOR RELEASING VIRUZIDS |
| US20190388336A1 (en) * | 2016-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Drug Delivery System for the Delivery of Antiviral Agents |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | Combination drug therapy |
| CR20220053A (es) * | 2019-08-13 | 2022-04-20 | Merck Sharp & Dohme | Sistema de administración de medicamentos para la administración de agentes antivíricos |
| EP4146302A4 (en) * | 2020-05-05 | 2024-05-22 | Merck Sharp & Dohme LLC | DRUG DELIVERY SYSTEM FOR DELIVERY OF ANTIVIRAL AGENTS AND CONTRACEPTIVES |
| WO2022046578A1 (en) * | 2020-08-25 | 2022-03-03 | Merck Sharp & Dohme Corp. | Injectable depot compositions for the delivery of antiviral agents |
-
2017
- 2017-02-09 JO JOP/2017/0038A patent/JOP20170038B1/ar active
- 2017-02-10 SG SG11201806783WA patent/SG11201806783WA/en unknown
- 2017-02-10 FI FIEP17706102.5T patent/FI3413897T3/fi active
- 2017-02-10 EA EA201891814A patent/EA201891814A1/ru unknown
- 2017-02-10 NZ NZ745065A patent/NZ745065A/en unknown
- 2017-02-10 US US15/430,016 patent/US10537589B2/en active Active
- 2017-02-10 TW TW112126073A patent/TW202417010A/zh unknown
- 2017-02-10 DK DK17706102.5T patent/DK3413897T3/da active
- 2017-02-10 CA CA3013473A patent/CA3013473C/en active Active
- 2017-02-10 JP JP2018541685A patent/JP6810972B2/ja active Active
- 2017-02-10 PL PL17706102.5T patent/PL3413897T3/pl unknown
- 2017-02-10 SI SI201731395T patent/SI3413897T1/sl unknown
- 2017-02-10 MY MYPI2018001425A patent/MY197090A/en unknown
- 2017-02-10 TW TW106104527A patent/TWI822652B/zh active
- 2017-02-10 MD MDE20181208T patent/MD3413897T2/ro unknown
- 2017-02-10 EP EP17706102.5A patent/EP3413897B1/en active Active
- 2017-02-10 UA UAA201809259A patent/UA126375C2/uk unknown
- 2017-02-10 CN CN202110783129.4A patent/CN113509480A/zh active Pending
- 2017-02-10 GE GEAP201715046A patent/GEP20217231B/en unknown
- 2017-02-10 AU AU2017217656A patent/AU2017217656B2/en active Active
- 2017-02-10 WO PCT/US2017/017283 patent/WO2017139519A1/en not_active Ceased
- 2017-02-10 KR KR1020257028942A patent/KR20250136420A/ko active Pending
- 2017-02-10 KR KR1020187025948A patent/KR102317570B1/ko active Active
- 2017-02-10 MX MX2018009763A patent/MX390604B/es unknown
- 2017-02-10 KR KR1020217012504A patent/KR20210049201A/ko not_active Ceased
- 2017-02-10 PT PT177061025T patent/PT3413897T/pt unknown
- 2017-02-10 TN TNP/2018/000267A patent/TN2018000267A1/en unknown
- 2017-02-10 LT LTEPPCT/US2017/017283T patent/LT3413897T/lt unknown
- 2017-02-10 BR BR112018016349A patent/BR112018016349A2/pt not_active Application Discontinuation
- 2017-02-10 CN CN201780010879.XA patent/CN108697727A/zh active Pending
- 2017-02-10 MX MX2022002925A patent/MX2022002925A/es unknown
- 2017-02-10 KR KR1020227029968A patent/KR20220126787A/ko not_active Ceased
- 2017-02-10 HU HUE17706102A patent/HUE063532T2/hu unknown
- 2017-02-10 RS RS20230656A patent/RS64448B1/sr unknown
- 2017-02-10 ES ES17706102T patent/ES2953535T3/es active Active
- 2017-02-10 IL IL260874A patent/IL260874B2/en unknown
- 2017-02-10 MX MX2022002924A patent/MX2022002924A/es unknown
- 2017-02-10 HR HRP20230935TT patent/HRP20230935T1/hr unknown
-
2018
- 2018-07-27 ZA ZA2018/05073A patent/ZA201805073B/en unknown
- 2018-08-08 CL CL2018002150A patent/CL2018002150A1/es unknown
- 2018-08-08 NI NI201800083A patent/NI201800083A/es unknown
- 2018-08-09 SV SV2018005733A patent/SV2018005733A/es unknown
- 2018-08-10 DO DO2018000183A patent/DOP2018000183A/es unknown
- 2018-08-13 PH PH12018501712A patent/PH12018501712A1/en unknown
-
2019
- 2019-12-11 US US16/710,875 patent/US11337991B2/en active Active
-
2020
- 2020-04-30 AU AU2020202866A patent/AU2020202866B2/en active Active
- 2020-09-11 JP JP2020153037A patent/JP7021314B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015456A patent/JP2022062170A/ja active Pending
- 2022-03-10 AU AU2022201686A patent/AU2022201686B2/en active Active
- 2022-04-08 US US17/658,547 patent/US12171776B2/en active Active
-
2023
- 2023-10-06 JP JP2023174548A patent/JP7559175B6/ja active Active
-
2024
- 2024-11-13 US US18/946,040 patent/US20250073254A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050277616A1 (en) * | 1995-06-07 | 2005-12-15 | Howard Owens | Thymine nucleosides with anti-hepatitis B virus activity |
| US7339053B2 (en) * | 2004-03-24 | 2008-03-04 | Yamasa Corporation | 4′-C-substituted-2-haloadenosine derivative |
| US20080153774A1 (en) * | 2004-03-24 | 2008-06-26 | Satoru Kohgo | 4' -C-substituted-2-haloadenosine derivative |
Non-Patent Citations (2)
| Title |
|---|
| CHERYL A. STODDART ET AL: "Oral Administration of the Nucleoside EFdA (4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
| MICHAEL MURPHEY-CORB,ET AL.: "Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4-Ethynyl-2-Fluoro-2-Deoxyadenosine In Vitro and In Vivo", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113194959A (zh) * | 2018-12-20 | 2021-07-30 | 默沙东公司 | Nrtti化合物的新型结晶形式 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12171776B2 (en) | Methods for treatment and prophylaxis of HIV and AIDS | |
| HK40054462A (en) | Methods for treatment and prophylaxis of hiv and aids | |
| EP3823632B1 (en) | Efda in combination with doravirine for use in treating f227c mutated hiv infections | |
| AU2018239257A1 (en) | HIV post-exposure prophylaxis | |
| EA042565B1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа | |
| HK1257347B (en) | Methods for treatment and prophylaxis of hiv and aids | |
| US7745455B2 (en) | Zalcitabine (ddC) boosted lamivudine (3TC) compositions for antiretroviral therapy | |
| US20220265689A1 (en) | Hiv pre-exposure prophylaxis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220902 Address after: new jersey Applicant after: MERCK SHARP & DOHME B.V. Address before: new jersey Applicant before: MERCK SHARP & DOHME Corp. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181023 |
|
| RJ01 | Rejection of invention patent application after publication |